Digest Network Come funziona
Network
/
Società
An
Non verificato

Ankyra Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

13 comunicati stampa

Guarda tutti i comunicati
15/10/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Industria
Ankyra Therapeutics to Present Data at SITC 2026 Supporting Anchored Immunotherapy with Multiple Cancer-Fighting Agonists for Localized Tumor Treatment
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
27/05/2026
Biotecnologia
Salute
Farmaceutica
Oncologia
Eventi
Ankyra Therapeutics Announces Presentations on Novel IL-12 Anchored Immunotherapy at 2026 ASCO
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
11/05/2026
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Ankyra Therapeutics Announces Preclinical Presentation of Anchored Immunotherapy Using Monoclonal Antibodies at PEGS Boston 2026
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
16/04/2026
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Ankyra Therapeutics Announces Clinical Presentations on Novel IL-12 Anchored Immunotherapy at AACR 2026
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
18/02/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Ankyra Therapeutics Presents First Preclinical Data on ANK-203, a Novel CD137-Anchored Immunotherapy Candidate, in Oral Session at AACR IO
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
15/12/2025
Mercato del lavoro
Oncologia
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO)
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
17/11/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Ankyra Therapeutics Announces First Patient Dosed in Phase 1b Trial Evaluating First-in-Class Anchored Immunotherapy in Combination with Immune Checkpoint Blockade in Patients with Lung Cancer
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
04/11/2025
Scienza
Veterinaria
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Industria
Ankyra Announces Publication of Phase 1 Clinical Data, and Will Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
28/04/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Ankyra Therapeutics Announces Phase 1 Clinical Data at the 2025 AACR Annual Meeting and the first patient has been dosed with tolododekin alfa and cemiplimab
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0
28/04/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Ankyra Therapeutics Announces Phase 1 Clinical Data at the 2025 AACR Annual Meeting and the first patient has been dosed with tolododekin alfa and cemiplimab
Fonte
Ankyra Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0